

August 17, 2004

**ATTN:** Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Revisions to Chapter III of the Communicable Disease Control Manual – "Immunization Program"

Please note the following revisions:

## (1) Section I – Introduction:

#### **Table of Contents:**

change of term from Immunization Certification to Immunization Competency.

# Page 4, Subsection 5.0 "Immunization Competency:"

- change of term from "Immunization Certification" to "Immunization Competency."
- notation of the provincial Immunization Competency Program being revised in May 2004

# Pages 5 – 9, Subsection 7.0 "History of Immunization Development in BC:"

re-dated due to additional content:

#### Page 6:

 1981 - regarding DPT, DT and Td adsorbed vaccines – notation that these vaccines contained thimerosal

#### Page 7:

 1994 – note that Pentavalent vaccine (diphtheria, pertussis, tetanus, polio, conjugate haemophilus influenzae type b) ( DPT/IPV/ActHIB) did not contain thimerosal

Administrative Circular # 2004:05



## Page 8:

 1997 – added notation that a hepatitis B vaccine catch-up program was provided to all grade 12 students

# Page 9:

- 2001 Thimerosal-free HBV for infants and children < 7 years of age (June 2001)
- Addition of new vaccine programs introduced in 2004

#### Page 11:

Pertussis toxoid 2.5 µg added to vaccine components list for TdaP

## (2) Section V – Anaphylaxis:

Page 4: removal of oral Benadryl® use from guidelines

Page 7: addition of Epinephrine strength (1:1,000) to top of chart

Page 8: removal of oral Benadryl®

# (3) Section VII – Biological Products:

## Page 6, Hepatitis A Vaccine Indications:

Inmates of provincial correctional facilities are eligible for hepatitis A vaccine.

# Page 9, Hepatitis A Vaccine, Avaxim™:

latex has been removed from the needle shield for this product.

# Page 16, Hepatitis B Vaccine Pre- exposure, Engerix®-B:

 the schedule for infants and children < 7 years of age is 0, 1, and 6 months, (and not 2 – 4 - 6 months).

#### Page 17, Hepatitis B Vaccine Pre- exposure, Engerix®-B:

deleted footnote regarding revaccination of non-responders.

#### Page 18, Hepatitis B Vaccine Pre-exposure, RecombivaxHB®:

- deleted footnote regarding revaccination of non-responders.
- deleted footnote regarding minimal intervals between vaccine doses.



## Page 28, Immune Globulin Preparations:

- for children 5 to 18 years inclusive, added 1" 1½" needle length, 20-25 gauge, vastus lateralis site and 1 3 ml volume
- for adults ≥ 19 years of age, added 1" 1½" needle length, 20-22 gauge, vastus lateralis site and 5 ml volume.

## Page 29, Immune Globulin Preparations or Blood: Timing Intervals:

• under "Indications" for measles prophylaxis, changed the wording from "normal contact" to "healthy contact".

#### Page 32, Influenza Vaccine, Fluviral®S/F:

 wording has been changed to direct the reader to the National Advisory Committee on Immunization statement on influenza vaccination for the current season.

## Page 34, Measles/Mumps/Rubella Vaccine:

updated the list of components of MMRII ™ vaccine.

# Page 37, Meningococcal C Conjugate Vaccine, Neis Vac- C:

 change to the timing and number of doses of Neis Vac- C for infants: infants from two months to twelve months of age receive two doses of vaccine, two months apart.

#### Page 38, Meningococcal C Conjugate Vaccine, Neis Vac- C:

 change to vaccine doses and timing for infants from two to twelve months of age, as above.

#### Page 43, Pneumococcal Polysaccharide Vaccine, Pneumo 23™:

• latex has been removed from the needle shield for this product.

#### Page 43a, Pneumococcal Polysaccharide Vaccine, Pneumovax® 23:

• new page, for the Merck Frosst pneumococcal polysaccharide vaccine.

#### Page 53, Tetanus-Diphtheria-Pertussis Vaccine, Adacel™:

 footnote added to indicate that high school students who missed their grade 9 booster should be given Adacel™.

#### Page 54, Tetanus-Diphtheria-Inactivated Poliomyelitis Adsorbed (Td/IPV):

clarification of the reinforcing vaccine dose (Td, 0.5 mL IM, every 10 years).



# Page 55, Tetanus Immune Globulin (TIG), Baytet™:

• added footnote indicating that TIG does not interfere with the development of active immunity from a tetanus-containing vaccine.

# Please remove and destroy the following pages from Chapter III of the Communicable Disease Control Manual – "Immunization Program":

Section 1 Introduction

Table of Contents

Pages 4,5,6,7 & 8

Pages 9 &11

Dated June 2003

Dated November 2002

Dated June 2003

Section V Anaphylaxis:

Pages 4, 7 & 8 Dated June 2003

**Section VII Biological Products:** 

Table of Contents

Pages 6, 34 & 55

Pages 16 & 18

Pages 17 & 54

Pages 28, 37 & 43

Pages 29 & 38

Pages 32

Dated July 2004

Dated August 2003

Dated June 2004

Dated November 2002

Dated December 2003

Dated June 2003

Dated September 2003

Page 32 Dated September 2003
Page 53 Dated January 2004

## Please insert the following replacement pages:

Section I Introduction:

Table of Contents

Pages 4, 5, 6, 7, 8, 9 & 11 Dated August 2004

Section V Anaphylaxis:

Pages 4, 7 & 8, 9 Dated August 2004

Section VII Biological Products:

Table of Contents

Pages 6, 9, 16, 17, 18, 28, 29, 32

34, 37, 38, 43, 43a, 53, 54 & 55 Dated August 2004



If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604) 660-6061, fax (604) 660-0197 or by e-mail to <a href="mailto:karen.pielak@bccdc.ca">karen.pielak@bccdc.ca</a> or <a href="mailto:cheryl.mcintyre@bccdc.ca">cheryl.mcintyre@bccdc.ca</a>

Sincerely,

David Patrick
Director
Epidemiology Services
BC Centre for Disease Control

#### DMP/kka

pc: Dr Perry Kendall Dr. Eric Young

Provincial Health Officer Deputy Provincial Health Officer Ministry of Health Services Ministry of Health Services

Dr. Bob Fisk Warren O'Briain Medical Consultant Executive Director

Non-Communicable Disease Comm Disease and Addiction Prevention

Ministry of Health Planning Ministry of Health Services

Valery Dubenko
Manager, Communicable Disease Prevention --Immunization
Communicable Disease and Addiction Prevention
Ministry of Health Services